glp 1 structure of [ 3 H]liraglutide (top) and the GLP-1 receptor agonists Crystal Structure of Glucagon-like Peptide-1

Genetic deletion of monocaylglyceride-acyltransferase-2 (MGAT2) and diacylglyceride-acyltransferase-1 (DGAT1), enzymes involved in the stepwise re-esterification of MAGs to triacylglycerides (TAGs) inside intestinal epithelial cells, results in a reduced GIP-response to oral oil gavage [65]

This particular molecule is exciting, more proof that glucagon agonism just works even without GIP

I have always thought, along with other colleagues for a long time, that you can start identifying groups that have lived with obesity for a very long period of time and they would somehow present differently metabolically and so on, and it would give us an understanding of what treatments would be better for someone, let's say, with long-term obesity versus someone with short-term obesity

In individuals with obesitywho frequently exhibit baseline micronutrient perturbations and altered iron metabolism [14,15,16,17]such adaptations may have amplified metabolic consequences

The FDA based its decision on results from the Researching Cardiovascular Events with a Weekly Incretin in Diabetes (REWIND) trial